June 9, 2025 – The Avax AI system, developed by knowledge-based company Med Fanavaran Plus, is ushering in a new era for medical diagnostics in Iran. Specializing in medical image analysis, Avax AI delivers cancer detection and tumor characterization with an accuracy exceeding 93 percent. The project represents six years of intensive research and a $4 million investment.

According to CEO Taghipour, Avax AI operates much like ChatGPT, but is purpose-built for the interpretation of medical images. The system can accurately determine cancer stages, differentiate between benign and malignant tumors, and analyze cardiovascular images with advanced artificial intelligence algorithms. So far, Avax AI has processed over 20,000 breast images for cancer detection, continually learning and improving its diagnostic performance.

The platform also features a secure, proprietary cloud capable of storing medical data for up to five years, supporting direct integration with new ultrasound devices. Taghipour noted that the company is advocating for the retirement of outdated ultrasound printers in favor of seamless data transfer to the Avax AI cloud—enhancing both data security and diagnostic quality.

In addition to advancing AI diagnostics, Med Fanavaran Plus has contributed to the localization of medical equipment. Before 2017, Iran spent nearly 62millionannuallyonultrasoundimports.Today,over500advanced,triple−probeultrasounddeviceshavebeendistributednationwide,eachpricedbelow62 million annually on ultrasound imports. Today, over 500 advanced, triple-probe ultrasound devices have been distributed nationwide, each priced below 12,000—less than the cost of a single imported probe.

With Avax AI and indigenized medical technologies, Iran is taking bold steps toward technological independence and improved healthcare quality—offering a model of innovation for other fields in the health technology sector